Targeting MYC using a small molecule inhibitor (MYCi975) not only eliminated CSCs, prevented metastasis, and overcame cisplatin resistance, but also promoted CD8+ T cell intratumor infiltration in HNSCC treated with cisplatin. Here, CD8A is linked to head and neck squamous cell carcinoma.